Correlation between quantified promoter methylation and enzymatic activity of O6-methylguanine-DNA methyltransferase in glioblastomas

Tumor Biology

Volumn 33, Issue 2, 2012, Pages 373-381

  Kishida, Yugo ^a   Natsume, Atsushi ^a   Toda, Hiroshi ^a   Toi, Yuki ^a   Motomura, Kazuya ^a   Koyama, Hiroko ^b   Matsuda, Keiji ^c   Nakayama, Osamu ^c   Sato, Makoto ^c   Suzuki, Masaaki ^b,e   Kondo, Yutaka ^d   Wakabayashi, Toshihiko ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Molecular Imaging Drug Discovery Institute   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e RIKEN   (Japan)

Author keywords

Bisulfite pyrosequencing; Functional assay; Methylation

Indexed keywords

BISULFITE; DNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; OLIGONUCLEOTIDE; ALKYLATING AGENT;

ARTICLE; CANCER TISSUE; CAPILLARY ELECTROPHORESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DNA METHYLATION; ENZYME ACTIVITY; ENZYME ASSAY; FLUOROMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PYROSEQUENCING; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; BRAIN TUMOR; CALIBRATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; TUMOR CELL LINE;

ALKYLATING AGENTS; BRAIN NEOPLASMS; CALIBRATION; CELL LINE, TUMOR; DNA; DNA METHYLATION; ELECTROPHORESIS, CAPILLARY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; OLIGONUCLEOTIDES; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC;

EID: 84860271002     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0319-1     Document Type: Article

References (28)

1. Hansen WK, Kelley MR. Review of mammalian DNA repair and translational implications. J Pharmacol Exp Ther. 2000;295:1-9.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96.
3. Silber JR, Blank A, Bobola MS, Ghatan S, Kolstoe DD, et al. O6- Methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res. 1999;5:807-14.
4. Gerson SL.MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004;4:296-307.
5. Natsume A, Ishii D, Wakabayashi T, Tsuno T, Hatano H, et al. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res. 2005;65:7573-9.
6. Natsume A, Wakabayashi T, Tsujimura K, Shimato S, Ito M, et al. The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer. 2008;122:2542-53.
7. Oi S, Natsume A, Ito M, Kondo Y, Shimato S, et al. Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells. J Neurooncol. 2009;92:15-22.
8. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350-4.
9. Kreklau EL, Limp-Foster M, Liu N, Xu Y, Kelley MR, et al. A novel fluorometric oligonucleotide assay to measure O6-methylguanine DNA methyltransferase, methylpurine DNA glycosylase, 8-oxoguanine DNA glycosylase and abasic endonuclease activities: DNA repair status in human breast carcinoma cells overexpressing methylpurine DNA glycosylase. Nucleic Acids Res. 2001;29:2558-66.
10. Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clin Cancer Res. 2006;12:328-31.
11. Reinhard J, Eichhorn U, Wiessler M, Kaina B. Inactivation of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors. Int J Cancer. 2001;93:373-9.
12. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
13. Brandes AA, Tosoni A, Franceschi E, Sotti G, Frezza G, et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol. 2009;27:1275-9.
14. Felsberg J, Rapp M, Loeser S, Fimmers R, Stummer W, et al. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res. 2009;15:6683-93.
15. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R. Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites. Biotechniques. 2003;35:146-50.
16. Tost J, Dunker J, Gut IG. Analysis and quantification of multiple methylation variable positions in CpG islands by pyrosequencing. Biotechniques. 2003;35:152-6.
17. Dupont JM, Tost J, Jammes H, Gut IG. De novo quantitative bisulfite sequencing using the pyrosequencing technology. Anal Biochem. 2004;333:119-27.
18. Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphate. Science. 1998;281:363-365.
19. Tost J, El abdalaoui H, Gut IG. Serial pyrosequencing for quantitative DNA methylation analysis. Biotechniques. 2006;40:721-2. 724, 726.
20. Uhlmann K, Brinckmann A, Toliat MR, Ritter H, Nurnberg P. Evaluation of a potential epigenetic biomarker by quantitative methyl-single nucleotide polymorphism analysis. Electrophoresis. 2002;23:4072-9.
21. Mellai M, Caldera V, Annovazzi L, Chio A, Lanotte M, et al. MGMT promoter hypermethylation in a series of 104 glioblastomas. Cancer Genomics Proteomics. 2009;6:219-27.
22. Cao VT, Jung TY, Jung S, Jin SG, Moon KS, et al. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Neurosurgery. 2009;65:866-75. discussion 875.
23. Preusser M, Charles Janzer R, Felsberg J, Reifenberger G, Hamou MF, et al. Anti-O6-methylguanine methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol. 2008;18:520-32.
24. Maxwell JA, Johnson SP, Quinn JA, McLendon RE, Ali- Osman F, et al. Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma. Mol Cancer Ther. 2006;5:2531-9.
25. Shah N, Lin B, Sibenaller Z, Ryken T, Lee H, et al. Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM. PLoS One. 2011;6: e16146. doi:10.1371/journal.pone. 0016146.
26. Brell M, Ibanez J, Tortosa A. O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and metaanalysis of correlation with methylation-specific polymerase chain reaction. BMC Cancer. 2011;11:35. doi:10.1186/1471-2407-11- 35.
27. Preuss I, Eberhagen I, Haas S, Eibl RH, Kaufmann M, et al. O6-methylguanine-DNA methyltransferase activity in breast and brain tumors. Int J Cancer. 1995;61:321-6.
28. Preuss I, Thust R, Kaina B. Protective effect of O6-methylguanine- DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs. Int J Cancer. 1996;65:506-12.